Couple Quark stories: One with ALNY, another with PFE.
++++++++++++++
Alnylam Grants Quark License To Develop Two RNAi Products
djones
DOW JONES NEWSWIRES
Alnylam Pharmaceuticals Inc. (ALNY) granted privately held Quark Biotech Inc.
licenses to discover, develop and commercialize RNAi therapeutics targeting the
p53 and RTP801 genes for certain diseases.
Terms of the deal weren't disclosed. However, Alnylam said the transaction
includes upfront, annual, and milestone payments, as well as royalties on sales.
The company also said Quark agreed to withdraw its opposition to the Kreutzer-
Limmer patent series currently granted in Europe.
Alnylam, Cambridge, Mass., said Quark, Fremont, Calif., has filed
investigational new drug applications for both targets, specifically in the case
of p53 for the treatment of renal failure and RTP801 for the treatment of ocular
diseases.
Earlier Tuesday, Quark entered into an agreement with Pfizer Inc. (PFE) in
which the New York-based pharmaceutical company acquired exclusive license to
Quark's RTP801 human gene and to molecules that modify its expression or
function. The agreement between Quark and Pfizer is subject to clearance by the
Federal Trade Commission. Terms of that deal weren't disclosed. |
